Mayne Pharma | MYX - 销售和管理费用



金融业
股票价格
AUD
资产
AUD 1.14B
现金及等价物
AUD 110.07M
销售成本
AUD 43.74M
流动资产
AUD 460.59M
流动负债
AUD 313.94M
债务
AUD 38.82M
EBIT
AUD -16.2M
EBITDA
AUD 20.9M
员工
450
EPS每股收益
AUD -0.15
股本和储备
AUD 454.19M
销售毛利
AUD 86.13M
债务利息支出
AUD 1.2M
贷款资金
AUD 2.66M
市值
AUD 277.34M
净收入
AUD -103.68M
营业费用
AUD 103.54M
营业利润
AUD -3.3M
普通股股本
AUD 81.25M
税前利润
AUD -14.7M
销售收入
AUD 212.07M
销售和管理费用
AUD 54.8M
股票
AUD 74.63M
贸易债权人
AUD 30.25M
应收帐款人
AUD 193.22M


销售和管理费用 更改 日
Ansell USD 274.8M 7.6M 2025-12
Avita Medical AUD 19.03M 1.95M 2025-12
Cochlear AUD 449.4M 214.45M 2025-12
CSL USD 1.23B 498M 2025-12
Healius AUD 393.4M 378.35M 2024-12
Integral Diagnostics AUD 169.98M 18.73M 2024-06
Medical Developments International AUD 2.84M 4.19M 2025-12
Nanosonics AUD 53.78M 26.93M 2025-12
Polynovo AUD 17.04M 1.91M 2025-12
Ramsay Health Care AUD 5.29B 3.2M 2024-12
ResMed USD 285.65M 9.96M 2026-03
Sigma Healthcare AUD 134.77M 9.73M 2024-12
Sonic Healthcare AUD 2.52B 2.46B 2024-12
Telix Pharmaceuticals AUD 107.02M 13.54M 2026-06